{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T03:21:40Z","timestamp":1790133700934,"version":"4.0.1"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T00:00:00Z","timestamp":1761264000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T00:00:00Z","timestamp":1761264000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82170186"],"award-info":[{"award-number":["82170186"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82370193"],"award-info":[{"award-number":["82370193"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82170166"],"award-info":[{"award-number":["82170166"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002858","name":"China Postdoctoral Science Foundation","doi-asserted-by":"publisher","award":["2021M691336"],"award-info":[{"award-number":["2021M691336"]}],"id":[{"id":"10.13039\/501100002858","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010246","name":"Postdoctoral Science Foundation of Jiangsu Province","doi-asserted-by":"publisher","award":["2021K083A"],"award-info":[{"award-number":["2021K083A"]}],"id":[{"id":"10.13039\/501100010246","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Project of National Key Clinical Specialty, Jiangsu Provincial Special Program of Medical Science","award":["BE2023775"],"award-info":[{"award-number":["BE2023775"]}]},{"name":"Jiangsu Province Capability Improvement Project through Science, Technology and Education","award":["ZDXK202209"],"award-info":[{"award-number":["ZDXK202209"]}]},{"name":"Jiangsu Province Hospital Clinical Competence Improvement Project","award":["JSPH-MB-2022-19"],"award-info":[{"award-number":["JSPH-MB-2022-19"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Med"],"DOI":"10.1186\/s12916-025-04418-y","type":"journal-article","created":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T14:11:02Z","timestamp":1761315062000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Zanubrutinib, lenalidomide and rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone as initial treatment in non\u2013germinal center B-cell diffuse large B-cell lymphoma: a multi-center phase 2 study by Jiangsu Cooperative Lymphoma Group (JCLG)"],"prefix":"10.1186","volume":"23","author":[{"given":"Yi","family":"Xia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Miao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siqi","family":"Qian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Run","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuchao","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyan","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bingzong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yeqin","family":"Sha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanning","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianyong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenyu","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huayuan","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,24]]},"reference":[{"issue":"9","key":"4418_CR1","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1056\/NEJMra2027612","volume":"384","author":"LH Sehn","year":"2021","unstructured":"Sehn LH, Salles G. Diffuse large B-cell lymphoma. N Engl J Med. 2021;384(9):842\u201358.","journal-title":"N Engl J Med"},{"issue":"25","key":"4418_CR2","doi-asserted-by":"publisher","first-page":"1937","DOI":"10.1056\/NEJMoa012914","volume":"346","author":"A Rosenwald","year":"2002","unstructured":"Rosenwald A, Wright G, Chan WC, Connors JM, Campo E, Fisher RI, et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med. 2002;346(25):1937\u201347.","journal-title":"N Engl J Med"},{"issue":"1","key":"4418_CR3","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1182\/blood-2003-05-1545","volume":"103","author":"CP Hans","year":"2004","unstructured":"Hans CP, Weisenburger DD, Greiner TC, Gascoyne RD, Delabie J, Ott G, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood. 2004;103(1):275\u201382.","journal-title":"Blood"},{"issue":"31","key":"4418_CR4","doi-asserted-by":"publisher","first-page":"3538","DOI":"10.1200\/JCO.2017.73.2784","volume":"35","author":"JP Leonard","year":"2017","unstructured":"Leonard JP, Kolibaba KS, Reeves JA, Tulpule A, Flinn IW, Kolevska T, et al. Randomized Phase II Study of R-CHOP With or Without Bortezomib in Previously Untreated Patients With Non-Germinal Center B-Cell-Like Diffuse Large B-Cell Lymphoma. J Clin Oncol. 2017;35(31):3538\u201346.","journal-title":"J Clin Oncol"},{"issue":"12","key":"4418_CR5","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1200\/JCO.20.01366","volume":"39","author":"GS Nowakowski","year":"2021","unstructured":"Nowakowski GS, Chiappella A, Gascoyne RD, Scott DW, Zhang Q, Jurczak W, et al. ROBUST: a phase III study of lenalidomide plus R-CHOP versus placebo plus R-CHOP in previously untreated patients with ABC-type diffuse large B-cell lymphoma. J Clin Oncol. 2021;39(12):1317\u201328.","journal-title":"J Clin Oncol"},{"issue":"15","key":"4418_CR6","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1200\/JCO.18.02403","volume":"37","author":"A Younes","year":"2019","unstructured":"Younes A, Sehn LH, Johnson P, Zinzani PL, Hong X, Zhu J, et al. Randomized phase III trial of ibrutinib and rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in non-germinal center B-cell diffuse large B-cell lymphoma. J Clin Oncol. 2019;37(15):1285\u201395.","journal-title":"J Clin Oncol"},{"issue":"25","key":"4418_CR7","doi-asserted-by":"publisher","first-page":"2216","DOI":"10.1182\/blood.2023022048","volume":"142","author":"DA Russler-Germain","year":"2023","unstructured":"Russler-Germain DA, Cliff ERS, Bartlett NL. Cell-of-origin effect of polatuzumab vedotin in diffuse large B-cell lymphoma: no ordinary subgroup analysis. Blood. 2023;142(25):2216\u20139.","journal-title":"Blood"},{"issue":"7277","key":"4418_CR8","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1038\/nature08638","volume":"463","author":"RE Davis","year":"2010","unstructured":"Davis RE, Ngo VN, Lenz G, Tolar P, Young RM, Romesser PB, et al. Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma. Nature. 2010;463(7277):88\u201392.","journal-title":"Nature"},{"issue":"4","key":"4418_CR9","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1182\/blood-2015-08-664086","volume":"127","author":"HS Walter","year":"2016","unstructured":"Walter HS, Rule SA, Dyer MJ, Karlin L, Jones C, Cazin B, et al. A phase 1 clinical trial of the selective BTK inhibitor ONO\/GS-4059 in relapsed and refractory mature B-cell malignancies. Blood. 2016;127(4):411\u20139.","journal-title":"Blood"},{"issue":"8","key":"4418_CR10","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1038\/nm.3884","volume":"21","author":"WH Wilson","year":"2015","unstructured":"Wilson WH, Young RM, Schmitz R, Yang Y, Pittaluga S, Wright G, et al. Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma. Nat Med. 2015;21(8):922\u20136.","journal-title":"Nat Med"},{"issue":"4","key":"4418_CR11","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1111\/bjh.12172","volume":"160","author":"LH Zhang","year":"2013","unstructured":"Zhang LH, Kosek J, Wang M, Heise C, Schafer PH, Chopra R. Lenalidomide efficacy in activated B-cell-like subtype diffuse large B-cell lymphoma is dependent upon IRF4 and cereblon expression. Br J Haematol. 2013;160(4):487\u2013502.","journal-title":"Br J Haematol"},{"issue":"22","key":"4418_CR12","doi-asserted-by":"publisher","first-page":"5058","DOI":"10.1002\/cncr.26135","volume":"117","author":"FJ Hernandez-Ilizaliturri","year":"2011","unstructured":"Hernandez-Ilizaliturri FJ, Deeb G, Zinzani PL, Pileri SA, Malik F, Macon WR, et al. Higher response to lenalidomide in relapsed\/refractory diffuse large B-cell lymphoma in nongerminal center B-cell-like than in germinal center B-cell-like phenotype. Cancer. 2011;117(22):5058\u201366.","journal-title":"Cancer"},{"key":"4418_CR13","doi-asserted-by":"crossref","unstructured":"Wilson WH, Wright GW, Huang DW, Hodkinson B, Balasubramanian S, Fan Y, et al. Effect of ibrutinib with R-CHOP chemotherapy in genetic subtypes of DLBCL. Cancer Cell. 2021;39(12):1643\u201353 e3.","DOI":"10.1016\/j.ccell.2021.10.006"},{"issue":"10","key":"4418_CR14","doi-asserted-by":"publisher","first-page":"2008","DOI":"10.1182\/bloodadvances.2022009389","volume":"7","author":"PWM Johnson","year":"2023","unstructured":"Johnson PWM, Balasubramanian S, Hodkinson B, Shreeve SM, Sun S, Srinivasan S, et al. Clinical impact of ibrutinib plus R-CHOP in untreated DLBCL coexpressing BCL2 and MYC in the phase 3 PHOENIX trial. Blood Adv. 2023;7(10):2008\u201317.","journal-title":"Blood Adv"},{"issue":"6","key":"4418_CR15","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1016\/j.ccr.2012.05.024","volume":"21","author":"Y Yang","year":"2012","unstructured":"Yang Y, Shaffer AL 3rd, Emre NC, Ceribelli M, Zhang M, Wright G, et al. Exploiting synthetic lethality for the therapy of ABC diffuse large B cell lymphoma. Cancer Cell. 2012;21(6):723\u201337.","journal-title":"Cancer Cell"},{"issue":"6","key":"4418_CR16","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1158\/2643-3230.BCD-21-0063","volume":"2","author":"AL Shaffer 3rd","year":"2021","unstructured":"Shaffer AL 3rd, Phelan JD, Wang JQ, Huang D, Wright GW, Kasbekar M, et al. Overcoming acquired epigenetic resistance to BTK inhibitors. Blood Cancer Discov. 2021;2(6):630\u201347.","journal-title":"Blood Cancer Discov"},{"issue":"13","key":"4418_CR17","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1182\/blood.2018891598","volume":"134","author":"A Goy","year":"2019","unstructured":"Goy A, Ramchandren R, Ghosh N, Munoz J, Morgan DS, Dang NH, et al. Ibrutinib plus lenalidomide and rituximab has promising activity in relapsed\/refractory non-germinal center B-cell-like DLBCL. Blood. 2019;134(13):1024\u201336.","journal-title":"Blood"},{"key":"4418_CR18","volume":"56","author":"R Ramchandren","year":"2023","unstructured":"Ramchandren R, Johnson P, Ghosh N, Ruan J, Ardeshna KM, Johnson R, et al. The iR(2) regimen (ibrutinib plus lenalidomide and rituximab) for relapsed\/refractory DLBCL: A multicentre, non-randomised, open-label phase 2 study. EClin Med. 2023;56:101779.","journal-title":"EClin Med"},{"issue":"4","key":"4418_CR19","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1200\/JCO.22.00597","volume":"41","author":"J Westin","year":"2023","unstructured":"Westin J, Davis RE, Feng L, Hagemeister F, Steiner R, Lee HJ, et al. Smart start: Rituximab, lenalidomide, and ibrutinib in patients with newly diagnosed large B-cell lymphoma. J Clin Oncol. 2023;41(4):745\u201355.","journal-title":"J Clin Oncol"},{"issue":"17","key":"4418_CR20","doi-asserted-by":"publisher","first-page":"7923","DOI":"10.1021\/acs.jmedchem.9b00687","volume":"62","author":"Y Guo","year":"2019","unstructured":"Guo Y, Liu Y, Hu N, Yu D, Zhou C, Shi G, et al. Discovery of Zanubrutinib (BGB-3111), a novel, potent, and selective covalent inhibitor of Bruton\u2019s tyrosine kinase. J Med Chem. 2019;62(17):7923\u201340.","journal-title":"J Med Chem"},{"issue":"4","key":"4418_CR21","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1056\/NEJMoa2211582","volume":"388","author":"JR Brown","year":"2023","unstructured":"Brown JR, Eichhorst B, Hillmen P, Jurczak W, Kazmierczak M, Lamanna N, et al. Zanubrutinib or ibrutinib in relapsed or refractory chronic lymphocytic leukemia. N Engl J Med. 2023;388(4):319\u201332.","journal-title":"N Engl J Med"},{"issue":"33","key":"4418_CR22","doi-asserted-by":"publisher","first-page":"5099","DOI":"10.1200\/JCO.22.02830","volume":"41","author":"MA Dimopoulos","year":"2023","unstructured":"Dimopoulos MA, Opat S, D\u2019Sa S, Jurczak W, Lee HP, Cull G, et al. Zanubrutinib versus ibrutinib in symptomatic Waldenstrom macroglobulinemia: final analysis from the randomized phase III aspen study. J Clin Oncol. 2023;41(33):5099\u2013106.","journal-title":"J Clin Oncol"},{"issue":"6","key":"4418_CR23","doi-asserted-by":"publisher","first-page":"1629","DOI":"10.1182\/bloodadvances.2020003698","volume":"6","author":"H Yang","year":"2022","unstructured":"Yang H, Xiang B, Song Y, Zhang H, Zhao W, Zou D, et al. Zanubrutinib monotherapy for relapsed or refractory non-germinal center diffuse large B-cell lymphoma. Blood Adv. 2022;6(6):1629\u201336.","journal-title":"Blood Adv"},{"issue":"2","key":"4418_CR24","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1007\/s00277-023-05498-7","volume":"103","author":"Y Wang","year":"2024","unstructured":"Wang Y, Xu J, Li P, Xu Y, Xue H, Liu P. Zanubrutinib-lenalidomide-rituximab (ZR(2)) in unfit diffuse large B-cell lymphoma: efficient and tolerant. Ann Hematol. 2024;103(2):499\u2013510.","journal-title":"Ann Hematol"},{"key":"4418_CR25","doi-asserted-by":"publisher","first-page":"1219167","DOI":"10.3389\/fimmu.2023.1219167","volume":"14","author":"H Geng","year":"2023","unstructured":"Geng H, Jia S, Zhang Y, Li J, Yang Q, Zeng L, et al. Efficacy and safety of zanubrutinib plus R-CHOP in treatment of non-GCB DLBCL with extranodal involvement. Front Immunol. 2023;14:1219167.","journal-title":"Front Immunol"},{"issue":"27","key":"4418_CR26","doi-asserted-by":"publisher","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","volume":"32","author":"BD Cheson","year":"2014","unstructured":"Cheson BD, Fisher RI, Barrington SF, Cavalli F, Schwartz LH, Zucca E, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014;32(27):3059\u201368.","journal-title":"J Clin Oncol"},{"issue":"12","key":"4418_CR27","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1200\/JCO.20.01375","volume":"39","author":"GS Nowakowski","year":"2021","unstructured":"Nowakowski GS, Hong F, Scott DW, Macon WR, King RL, Habermann TM, et al. Addition of lenalidomide to R-CHOP improves outcomes in newly diagnosed diffuse large B-cell lymphoma in a randomized phase II US intergroup study ECOG-ACRIN E1412. J Clin Oncol. 2021;39(12):1329\u201338.","journal-title":"J Clin Oncol"},{"issue":"15_suppl","key":"4418_CR28","doi-asserted-by":"publisher","first-page":"7508","DOI":"10.1200\/JCO.2019.37.15_suppl.7508","volume":"37","author":"J Westin","year":"2019","unstructured":"Westin J, Nastoupil LJ, Fayad L, Hagemeister FB, Oki Y, Turturro F, et al. Smart start: Final results of rituximab, lenalidomide, and ibrutinib lead in prior to combination with chemotherapy for patients with newly diagnosed diffuse large B-cell lymphoma. J Clin Oncol. 2019;37(15_suppl):7508\u20137508.","journal-title":"J Clin Oncol"},{"key":"4418_CR29","doi-asserted-by":"crossref","unstructured":"Wright GW, Huang DW, Phelan JD, Coulibaly ZA, Roulland S, Young RM, et al. A Probabilistic Classification Tool for Genetic Subtypes of Diffuse Large B Cell Lymphoma with Therapeutic Implications. Cancer Cell. 2020;37(4):551\u201368 e14.","DOI":"10.1016\/j.ccell.2020.03.015"},{"issue":"2","key":"4418_CR30","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1182\/blood.2023023789","volume":"145","author":"DA Qualls","year":"2025","unstructured":"Qualls DA, Armand P, Salles GA. The current landscape of frontline large B-cell lymphoma trials. Blood. 2025;145(2):176\u201389.","journal-title":"Blood"},{"issue":"20","key":"4418_CR31","doi-asserted-by":"publisher","first-page":"4021","DOI":"10.1182\/blood-2012-10-460063","volume":"121","author":"S Hu","year":"2013","unstructured":"Hu S, Xu-Monette ZY, Tzankov A, Green T, Wu L, Balasubramanyam A, et al. MYC\/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from the International DLBCL Rituximab-CHOP Consortium Program. Blood. 2013;121(20):4021\u201331.","journal-title":"Blood"},{"issue":"24","key":"4418_CR32","doi-asserted-by":"publisher","first-page":"4622","DOI":"10.1002\/cncr.31646","volume":"124","author":"PA Riedell","year":"2018","unstructured":"Riedell PA, Smith SM. Double hit and double expressors in lymphoma: definition and treatment. Cancer. 2018;124(24):4622\u201332.","journal-title":"Cancer"},{"issue":"2","key":"4418_CR33","volume":"13","author":"AA Hashmi","year":"2021","unstructured":"Hashmi AA, Iftikhar SN, Nargus G, Ahmed O, Asghar IA, Shirazi UA, et al. Double-Expressor Phenotype (BCL-2\/c-MYC Co-expression) of Diffuse Large B-Cell Lymphoma and Its Clinicopathological Correlation. Cureus. 2021;13(2):e13155.","journal-title":"Cureus"},{"issue":"5","key":"4418_CR34","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1158\/1078-0432.CCR-21-2949","volume":"28","author":"ZY Xu-Monette","year":"2022","unstructured":"Xu-Monette ZY, Wei L, Fang X, Au Q, Nunns H, Nagy M, et al. Genetic subtyping and phenotypic characterization of the immune microenvironment and MYC\/BCL2 double expression reveal heterogeneity in diffuse large B-cell lymphoma. Clin Cancer Res. 2022;28(5):972\u201383.","journal-title":"Clin Cancer Res"},{"key":"4418_CR35","doi-asserted-by":"crossref","unstructured":"Phelan JD, Scheich S, Choi J, Wright GW, Haupl B, Young RM, et al. Response to Bruton's tyrosine kinase inhibitors in aggressive lymphomas linked to chronic selective autophagy. Cancer Cell. 2024;42(2):238\u201352 e9.","DOI":"10.1016\/j.ccell.2023.12.019"},{"issue":"20","key":"4418_CR36","doi-asserted-by":"publisher","first-page":"1759","DOI":"10.1182\/blood.2019003535","volume":"135","author":"SE Lacy","year":"2020","unstructured":"Lacy SE, Barrans SL, Beer PA, Painter D, Smith AG, Roman E, et al. Targeted sequencing in DLBCL, molecular subtypes, and outcomes: a haematological malignancy research network report. Blood. 2020;135(20):1759\u201371.","journal-title":"Blood"},{"issue":"28","key":"4418_CR37","doi-asserted-by":"publisher","first-page":"2845","DOI":"10.1200\/JCO.2018.78.5246","volume":"36","author":"DM Kurtz","year":"2018","unstructured":"Kurtz DM, Scherer F, Jin MC, Soo J, Craig AFM, Esfahani MS, et al. Circulating tumor DNA measurements as early outcome predictors in diffuse large B-cell lymphoma. J Clin Oncol. 2018;36(28):2845\u201353.","journal-title":"J Clin Oncol"},{"key":"4418_CR38","doi-asserted-by":"crossref","unstructured":"Sworder BJ, Kurtz DM, Alig SK, Frank MJ, Shukla N, Garofalo A, et al. Determinants of resistance to engineered T cell therapies targeting CD19 in large B cell lymphomas. Cancer Cell. 2023;41(1):210\u201325 e5.","DOI":"10.1016\/j.ccell.2022.12.005"},{"issue":"3","key":"4418_CR39","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-008450","volume":"12","author":"H Zou","year":"2024","unstructured":"Zou H, Liu W, Wang X, Wang Y, Wang C, Qiu C, et al. Dynamic monitoring of circulating tumor DNA reveals outcomes and genomic alterations in patients with relapsed or refractory large B-cell lymphoma undergoing CAR T-cell therapy. J Immunother Cancer. 2024;12(3):e008450.","journal-title":"J Immunother Cancer"},{"issue":"11","key":"4418_CR40","doi-asserted-by":"publisher","first-page":"6092","DOI":"10.1073\/pnas.1921187117","volume":"117","author":"J Choi","year":"2020","unstructured":"Choi J, Phelan JD, Wright GW, Haupl B, Huang DW, Shaffer AL 3rd, et al. Regulation of B cell receptor-dependent NF-kappaB signaling by the tumor suppressor KLHL14. Proc Natl Acad Sci U S A. 2020;117(11):6092\u2013102.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"7247","key":"4418_CR41","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1038\/nature07968","volume":"459","author":"M Compagno","year":"2009","unstructured":"Compagno M, Lim WK, Grunn A, Nandula SV, Brahmachary M, Shen Q, et al. Mutations of multiple genes cause deregulation of NF-kappaB in diffuse large B-cell lymphoma. Nature. 2009;459(7247):717\u201321.","journal-title":"Nature"},{"issue":"12","key":"4418_CR42","doi-asserted-by":"publisher","first-page":"1863","DOI":"10.1182\/blood.2021012852","volume":"139","author":"L Meriranta","year":"2022","unstructured":"Meriranta L, Alkodsi A, Pasanen A, Lepisto M, Mapar P, Blaker YN, et al. Molecular features encoded in the ctDNA reveal heterogeneity and predict outcome in high-risk aggressive B-cell lymphoma. Blood. 2022;139(12):1863\u201377.","journal-title":"Blood"},{"issue":"4","key":"4418_CR43","doi-asserted-by":"publisher","DOI":"10.1016\/j.gendis.2023.101116","volume":"11","author":"Y Xia","year":"2024","unstructured":"Xia Y, Wang L, Liang J, Shen H, Wu J, Yin H, et al. Genotyping on circulating tumor DNA improves mutation detection rate in high-risk diffuse large B-cell lymphoma. Genes Dis. 2024;11(4):101116.","journal-title":"Genes Dis"}],"container-title":["BMC Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-025-04418-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12916-025-04418-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-025-04418-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T14:11:06Z","timestamp":1761315066000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcmedicine.biomedcentral.com\/articles\/10.1186\/s12916-025-04418-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,24]]},"references-count":43,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["4418"],"URL":"https:\/\/doi.org\/10.1186\/s12916-025-04418-y","relation":{},"ISSN":["1741-7015"],"issn-type":[{"value":"1741-7015","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,24]]},"assertion":[{"value":"15 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Institutional Research Board of Jiangsu Province Hospital and was carried out following the Declaration of Helsinki. The study is registered in ClinicalTrials.gov 01.20.2022, with the identification number NCT05200312. All patients provided written informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"583"}}